摘要
生长激素抑制素是一种循环性激素释放抑制肽,具有对其所有五生长激素抑制素受体(SSTR)的高结合亲和力。生长激素抑制素负调节细胞增殖和通过其同源受体的激活释放多激素。各种各样的生长激素抑制素类似物,一些有高亲和力和受体亚型的选择性,已被合成和开发。一定的长效生长激素抑制素类似物奥曲肽、兰瑞肽和帕瑞肽已被临床应用于人类的疾病,例如那些由生长激素的过度释放引起的疾病(肢端肥大症),或由促肾上腺皮质激素过度释放引起的疾病(库欣综合征),和用于类癌综合征的治疗。调查在这些长效生长激素抑制素的新生物活性及它们的可能临床应用也仍在进行中。此外,新的生长激素抑制素类似物正计划和发展到靶向不同的受体亚型或模拟自然的生长激素抑制素的多生物学特性。另外,由于生长激素抑制素受体,尤其是生长激素抑制素受体2,异常表达在许多肿瘤组织中细胞和肿瘤血管,内化的生长激素抑制素类似物目前被作为药物运输载体用以受体靶向疗法。本文将讨论开发和应用生长激素抑制素及其类似物的最近进展。
关键词: 激素,生长激素抑制素,生长激素抑制素类似物,生长激素抑制素受体,靶向受体。
Current Drug Targets
Title:Somatostatin and its Analogs
Volume: 17 Issue: 5
Author(s): Lichun Sun and David H. Coy
Affiliation:
关键词: 激素,生长激素抑制素,生长激素抑制素类似物,生长激素抑制素受体,靶向受体。
摘要: Somatostatin (SST) is a cyclic hormone-release inhibitory peptide that has high binding affinity to all of its five SST receptors (SSTRs). SST negatively regulates cell proliferation and the release of multiple hormones via activation of its cognate receptors. A variety of SST analogs, some with high affinity and selectivity of receptor subtypes, have been synthesized and developed. Certain longacting SST analogs such as octreotide, lanreotide and pasireotide have been clinically applied to the treatment of human diseases such as those caused by excessive release of growth hormone (acromegaly), or adrenocorticotropic hormone (Cushing’s syndrome), and for the treatment of carcinoid syndrome. Investigations into new biological activities of these long-acting SSTs and their possible clinical applications are also still ongoing. Also, novel SST analogs are being designed and developed to target different receptor subtype(s) or mimic natural SST’s multiple biological properties. Additionally, since SSTRs, especially SSTR2, are aberrantly expressed in many cancer cells and tumor blood vessels, internalizing SST analogs is currently being used as drug-delivery vehicle for the application of receptor-targeted therapeutics. This review will discuss recent advances in the development and applications of SST and its analogs
Export Options
About this article
Cite this article as:
Lichun Sun and David H. Coy , Somatostatin and its Analogs, Current Drug Targets 2016; 17 (5) . https://dx.doi.org/10.2174/1389450116666141205163548
DOI https://dx.doi.org/10.2174/1389450116666141205163548 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DNA Double Strand Breaks Repair Inhibitors: Relevance as Potential New Anticancer Therapeutics
Current Medicinal Chemistry Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science Proteasome Inhibitors in Cancer Therapy
Current Drug Targets Enzymatic Properties and Physiological Roles of Cytosolic 5’-Nucleotidase II.
Current Medicinal Chemistry Regulation of Transcription Factors by Heterotrimeric G Proteins
Current Molecular Pharmacology Histone Deacetylases: Anti-Angiogenic Targets in Cancer Therapy
Current Cancer Drug Targets Natural Products as Promising Drug Candidates for the Treatment of Alzheimer’s Disease: Molecular Mechanism Aspect
Current Neuropharmacology Selective α7 Nicotinic Acetylcholine Receptor Ligands
Current Medicinal Chemistry Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment
Current Pharmaceutical Design Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets Novel Targets for Apoptosis Modulation: BAG3 Protein and Other Co- Chaperones
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Ion Channels as Important Targets for Antiepileptic Drug Design
Current Drug Targets Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies
Current Pharmaceutical Design Neurotransmitters and Microglial-Mediated Neuroinflammation
Current Protein & Peptide Science MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Current Medicinal Chemistry Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat
Current Drug Targets Part-Time α-Secretases: The Functional Biology of ADAM 9, 10 and 17
Current Alzheimer Research Brain Senescence and Neuroprotective Dietary Components
Central Nervous System Agents in Medicinal Chemistry NGS of microRNAs Involved in Cardioprotection Induced by Sevoflurane Compared to Propofol in Myocardial Revascularization Surgery: The ACDHUVV-16 Clinical Trial
Current Medicinal Chemistry GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer’s Disease Patients
Current Alzheimer Research